A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG-012 Injections in Patients with Alport Syndrome
A study for patients with Alport Syndrome using study drug RG-012
Sponsor: Regulus Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAQ9729
U.S. Govt. ID: NCT02855268
Contact: Michael Toledo: 212-305-6842 / mt3013@columbia.edu
Additional Study Information: Alport syndrome is a condition people are born with. It causes damage to the kidneys over time. The purpose of this research study is to evaluate the safety and effectiveness (how well it works) of RG-012 compared to placebo (an inactive substance that contains no medicine) as a treatment for patients with Alport syndrome. We will also look at how the body absorbs and breaks down RG-012 and how RG-012affects the body.Sponsor delayed initiation: 6/13/2017
This study is closed
Investigator
Gerald Appel, MD
Do You Qualify?
Have you been diagnosed with Alport Syndrome? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Michael Toledo
mt3013@columbia.edu
212-305-6842